Figure 4.
Like sorafenib, cabozantinib does not have potent activity against FLT3/D835Y variant receptor tyrosine kinase. FLT3 indicates FMS-like tyrosine kinase 3; pFLT3, phosphorylated FMS-like tyrosine kinase 3.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.